Association Between a National Insurer's Pay-for-Performance Program for Oncology and Changes in Prescribing of Evidence-Based Cancer Drugs and Spending.
Justin E BekelmanAtul GuptaEzra FishmanDavid DebonoMichael J FischYing LiuGosia SylwestrzakJohn BarronAmol S NavathePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
P4P programs may be effective in increasing evidence-based cancer drug prescribing, but may not yield cost savings.